The objective of this study was to determine the maximum tolerated dose and safety of LR-103, a Vitamin D analogue, in patients with advanced cancer.
Methods
In Step A, patients received oral LR-103 once daily in 14-day cycles with intra-patient dose escalation per accelerated dose escalation design. Dose limiting toxicity for Step A was defined as ≥grade 2 hypercalcemia and/or >grade 2 other toxicities. Starting dose was 5 µg/day. Step B used a 3+3 design starting at Step A maximum tolerated dose with 28-day cycles. Dose limiting toxicity was defined as ≥grade 3 hypercalcemia or any grade 3 or 4 non-hematologic toxicity, except hypercalciuria.
Results
Twenty-one patients were enrolled; eight were treated in Step A. At dose level 3 (15 µg/day), two patients had dose limiting toxicity. One had grade 4 hyperuricemia. The other had grade 4 GGT plus grade 3 alkaline phosphatase, fatigue and urinary tract infection (UTI). Dose level 2 (10 µg/day) was the maximum tolerated dose for Step A and was starting dose for Step B. The dose was escalated to dose level 5 (30 µg/day) with a patient experiencing grade 3 dose limiting toxicity of hypercalcemia. The study was discontinued before reaching the maximum tolerated dose due to sponsor decision. Modest increases in serum osteocalcin and calcium and decrease in parathyroid hormone were noted. Best response was stable disease; four patients were on therapy for six months or longer.
Conclusion
Step A dose limiting toxicities limited accelerated dose escalation. The maximum tolerated dose of LR-103 was not reached prior to study termination and this agent is no longer being developed.
Albanes D, Mondul AM, Yu K, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prevent [a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology] 2011; 20: 1850–1860.
2.
GarlandCFComstockGWGarlandFC. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet1989; 2: 1176–1178.
3.
GarlandFCGarlandCFGorhamED. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med1990; 19: 614–622.
4.
John EM, Schwartz GG, Dreon DM, et al. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prevent [a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology] 1999; 8: 399–406.
5.
LefkowitzESGarlandCF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol1994; 23: 1133–1136.
6.
Ordonez-Mena JM, Schottker B, Haug U, et al. Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prevent [a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology] 2013; 22: 905–916.
7.
ShinMHHolmesMDHankinsonSE. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst2002; 94: 1301–1311.
8.
ChouvetCVicardEDevonecM. 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem1986; 24: 373–376.
9.
ColstonKWChanderSKMackayAG. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol1992; 44: 693–702.
10.
RossiJFDurieBGDuperrayC. Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Cancer Res1988; 48: 1213–1216.
11.
ColstonKWJamesSYOfori-KuraguEA. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer1997; 76: 1017–1020.
12.
MathiasenISColstonKWBinderupL. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol1993; 46: 365–371.
13.
NagakuraKAbeESudaT. Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int1986; 29: 834–840.
14.
SchwartzGGOelerTAUskokovicMR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res1994; 14: 1077–1081.
15.
SkowronskiRJPeehlDMFeldmanD. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology1995; 136: 20–26.
16.
GrossCStameyTHancockS. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol1998; 159: 2035–2039; discussion 9–40.
17.
OsbornJLSchwartzGGSmithDC. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol1995; 1: 195–198.
18.
BeerTMEilersKMGarzottoM. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol2003; 21: 123–128.
19.
BeerTMLemmonDLoweBA. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer2003; 97: 1217–1224.
20.
HellstromERobertKHSamuelssonJ. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol1990; 45: 255–261.
21.
MellibovskyLDiezAPerez-VilaE. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol1998; 100: 516–520.
22.
SmithDCJohnsonCSFreemanCC. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res1999; 5: 1339–1345.
23.
HorstRLKoszewskiNJReinhardtTA. 1 alpha-hydroxylation of 24-hydroxyvitamin D2 represents a minor physiological pathway for the activation of vitamin D2 in mammals. Biochemistry1990; 29: 578–582.
24.
MawerEBJonesGDaviesM. Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrin Metab1998; 83: 2156–2166.
25.
StrugnellSByfordVMakinHL. 1 alpha,24(S)-dihydroxyvitamin D2: a biologically active product of 1 alpha-hydroxyvitamin D2 made in the human hepatoma, Hep3B. Biochem J1995; 310(Pt 1): 233–241.
26.
JonesGByfordVMakinHL. Anti-proliferative activity and target cell catabolism of the vitamin D analog 1 alpha,24(S)-(OH)2D2 in normal and immortalized human epidermal cells. Biochem Pharmacol1996; 52: 133–140.
27.
LevyYKnutsonJCBishopC. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines. Anticancer Res1998; 18: 1769–1775.
28.
BauerJAThompsonTAChurchDR. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Prostate2003; 55: 159–167.
29.
WigingtonDPUrbenCMStrugnellSA. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res2004; 24: 2905–2912.
30.
ZinserGMTribbleEValranceM. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors. Anticancer Res2005; 25: 235–241.
31.
KnutsonJCLeVanLWValliereCR. Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol. Biochem Pharmacol1997; 53: 829–837.
32.
SimonRFreidlinBRubinsteinL. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst1997; 89: 1138–1147.
33.
CareyLARugoHSMarcomPK. TBCRC 001: Randomized phase II study of Cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol2012; 30: 2615–2623.
34.
TherassePArbuckSGEisenhauerEA. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000; 92: 205–216.
35.
DussoASBrownAJSlatopolskyE. Vitamin D. Am J Physiol Renal Physiol2005; 289: F8–28.
36.
SlapakCADesforgesJFFogarenT. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol1992; 41: 178–183.
37.
ScherHIJiaXChiK. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol2011; 29: 2191–2198.
